William Blair Predicts Biogen’s Q2 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Research analysts at William Blair lifted their Q2 2025 earnings per share (EPS) estimates for Biogen in a report issued on Monday, July 14th. William Blair analyst M. Minter now anticipates that the biotechnology company will post earnings per share of $4.11 for the quarter, up from their previous forecast of $4.09. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen’s FY2025 earnings at $14.74 EPS, FY2026 earnings at $15.94 EPS, Q1 2027 earnings at $4.37 EPS and Q2 2027 earnings at $4.95 EPS.

Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.26 by ($0.24). The firm had revenue of $2.43 billion during the quarter, compared to analyst estimates of $2.25 billion. Biogen had a net margin of 15.07% and a return on equity of 14.03%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.67 earnings per share.

Several other brokerages have also recently commented on BIIB. Oppenheimer set a $205.00 price target on shares of Biogen in a research report on Friday, May 2nd. Canaccord Genuity Group decreased their target price on Biogen from $265.00 to $220.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Royal Bank Of Canada set a $213.00 target price on Biogen and gave the stock an “outperform” rating in a research note on Wednesday, June 25th. Truist Financial cut their price target on Biogen from $210.00 to $199.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Finally, Mizuho decreased their price objective on Biogen from $207.00 to $169.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Twenty analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $188.48.

Biogen Trading Up 0.8%

Shares of BIIB stock opened at $128.46 on Wednesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.01 and a current ratio of 1.44. The stock has a market capitalization of $18.82 billion, a P/E ratio of 12.68, a price-to-earnings-growth ratio of 1.02 and a beta of 0.14. The company has a 50 day moving average price of $128.83 and a 200 day moving average price of $133.65. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $236.48.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lee Danner & Bass Inc. purchased a new stake in shares of Biogen during the 4th quarter worth approximately $25,000. Opal Wealth Advisors LLC acquired a new position in Biogen during the first quarter worth $26,000. Vision Financial Markets LLC purchased a new stake in Biogen during the first quarter worth $27,000. Greykasell Wealth Strategies Inc. acquired a new stake in Biogen in the first quarter valued at $27,000. Finally, Colonial Trust Co SC increased its position in shares of Biogen by 9,300.0% in the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 186 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Biogen

In related news, insider Rachid Izzar sold 2,223 shares of the firm’s stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the sale, the insider owned 6,330 shares in the company, valued at $854,550. This trade represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.18% of the stock is currently owned by company insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.